Apeloa Pharmaceutical Subsidiary Secures Marketing Approval for Prostate Cancer Drug API

Apeloa Pharmaceutical's Deuterated Enzalutamide API Receives Marketing Approval for Chemical Drug Substance Application

Apeloa Pharmaceutical's Wholly Owned Unit Gains Approval for Deuterated Enzalutamide API Marketing Application

Apeloa Honored with Frost & Sullivan's 2026 Global CDMO Company of the Year Award

Apeloa Pharmaceutical Subsidiary Gets US Abbreviated Drug Approval for Anti-Epileptic Tablets

Apeloa Pharma's Subsidiary Secures FDA Nod for Brivaracetam Tablets

Apeloa Pharmaceutical Gets China Marketing Nod for Anti-Infection API

Apeloa Pharmaceutical Secures Regulatory Nod for Cefditoren Pivoxil API in China

Apeloa Pharmaceutical's Pentoxifylline Extended-Release Tablets Secure Official Drug Approval

Apeloa Pharmaceutical's Unit Gets Nod to Market Fulzerasib API

Apeloa Pharmaceutical Subsidiary Gains Approval for Fuzereisai Active Ingredient Application

Apeloa Pharmaceutical Partners with Jitai Technology for CDMO Business

Apeloa Pharmaceutical Unit Wins China Approval for Levocarnitine Oral Solution; Shares Up 5%

Apeloa Pharmaceutical Unit Secures Drug Registration Certificate for Levocarnitine Oral Solution

Apeloa Pharmaceutical Unit Signs Cooperation Agreement With Two Biotech Firms; Shares Down 3%

Apeloa Pharmaceutical Obtains EU Certificate for Gabapentin; Shares Down 2%

Apeloa Pharmaceutical's Subsidiary Secures European CEP for Gabapentin API

Apeloa Pharmaceutical to Set Up 10 Million Yuan Joint Venture

Apeloa Pharmaceutical to Form Joint Venture with Related Parties for Biopharmaceutical Expansion

Apeloa Pharmaceutical's Subsidiary Secures Drug Registration Certificate for Sodium Valproate Sustained-Release Tablets (I)